[
    [
        {
            "time": "2018-05-01",
            "original_text": "Oral Semaglutide May Drive Solid Growth for NVO Going Forward",
            "features": {
                "keywords": [
                    "Semaglutide",
                    "solid growth",
                    "NVO"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Oral Semaglutide May Drive Solid Growth for NVO Going Forward",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-01",
            "original_text": "Ozempic Is Expected to Boost GLP-1 Drug Class Trajectory in 2018",
            "features": {
                "keywords": [
                    "Ozempic",
                    "GLP-1",
                    "boost"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Ozempic Is Expected to Boost GLP-1 Drug Class Trajectory in 2018",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-03-01",
            "original_text": "Victoza Continues to Lead in the GLP-1 Segment in 2018",
            "features": {
                "keywords": [
                    "Victoza",
                    "GLP-1",
                    "lead"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Victoza Continues to Lead in the GLP-1 Segment in 2018",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-04-01",
            "original_text": "GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk",
            "features": {
                "keywords": [
                    "GLP-1",
                    "growth",
                    "Novo Nordisk"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]